In a recent publication, researchers from The First Affiliated Hospital of Zhengzhou University (China) and collaborators investigated the association between phosphoglycerate kinase 1 (PGK1) expression in thyroid cancer tissues and clinicopathological features, postoperative recurrence and prognosis in papillary thyroid carcinoma (PTC). These observations may help advance clinical assessment and provide references for intervention strategies.
Cardiff Oncology Inc.’s mid-stage and ongoing clinical trial of its PLK1 inhibitor in colorectal cancer produced promising data but the company’s stock lost a quarter of its value on July 30 because of second-quarter losses. The randomized phase II study of onvansertib combined with a standard-of-care treatment in first-line, RAS-mutated metastatic colorectal cancer produced a 49% confirmed objective response rate at the 30-mg dose level compared to 30% in the control arm.
The news that Vinay Prasad has stepped down as CBER director at the U.S. FDA had some biotech stocks literally jumping in joy as the market opened July 30. Meanwhile, Prasad’s decisions regarding vaccine development, as well as actions by Makary and HHS Secretary Robert Kennedy, are coming under fire.
Radiopharm Theranostics Ltd. announced that the U.S. FDA has cleared the IND application for betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7-H3 that is highly expressed in tumors and not in healthy tissues.
Simcere Zaiming Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting zinc transporter ZIP6 (SLC39A6; LIV-1) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently bound to toll-like receptor 7 (TLR7) and/or toll-like receptor 8 (TLR8) agonist through a linker reported to be useful for the treatment of cancer.
Sevenless Therapeutics Ltd. has patented son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, parkinsonism, neurofibromatosis type 1, atopic dermatitis and cholestasis, among others.
Characteristics of the tumor microenvironment are likely to contribute to the aggressiveness of triple-negative breast cancer (TNBC) and the extremely poor prognosis of those who suffer it. By analyzing patterns of gene expression in cancer-associated fibroblasts from TNBC tumors, researchers in China identified the PLAU gene as a driver of aggressive phenotype.
Immune checkpoint inhibitor therapy has proven effective against many types of solid tumors, but not many subtypes of ovarian cancer, including the rare subtype of ovarian clear cell carcinoma (OCCC). Now, researchers have identified a subtype of OCCC that involves inactivating mutations in the gene PPP2R1A and that responds well to immune checkpoint inhibitor therapy.
RSS
